This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Futibatinib (Lytgobi) is a rare alkyne-containing, irreversible FGFR1-4 inhibitor that received accelerated approval from the FDA in September 2022. Structurally…
Article
9 months ago ●
6 mins read
Billion-Dollar Molecules: Etavopivat, an Allosteric PKR Kinase Activator for Sickle Cell Disease Abstract. Novo Nordisk has acquired Forma Therapeutics for…
Article
9 months ago ●
6 mins read
Omidenepag isopropyl (Omlonti) is a prodrug of a prostaglandin E2 (EP2) receptor agonist that reduces pressure in the eye. Upon…
Article
9 months ago ●
6 mins read
After evaluating thousands of articles and hundreds of candidates, a brain-penetrant pre-mRNA splicing modulator, a gut-restricted candidate for Parkinson’s disease…
Article
9 months ago ●
1 min read
Since the 2014 discoveries that thalidomide-like compounds “glue” together the cereblon (CRBN) unit of the ubiquitin E3 ligase complex and…
Article
9 months ago ●
13 mins read
Today, ozanimod is a likely megablockbuster drug approved for ulcerative colitis and multiple sclerosis. But before it became the first…
Article
10 months ago ●
9 mins read
Load More
